Czech National Bank Acquires 5,048 Shares of DexCom, Inc. (NASDAQ:DXCM)

Czech National Bank raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,737 shares of the medical device company's stock after acquiring an additional 5,048 shares during the period. Czech National Bank's holdings in DexCom were worth $6,128,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Rhumbline Advisers lifted its position in shares of DexCom by 4.3% during the 1st quarter. Rhumbline Advisers now owns 809,803 shares of the medical device company's stock worth $55,301,000 after purchasing an additional 33,574 shares during the last quarter. Bowman & Co S.C. increased its position in DexCom by 27.8% in the 1st quarter. Bowman & Co S.C. now owns 7,054 shares of the medical device company's stock worth $482,000 after buying an additional 1,535 shares during the period. Fifth Third Wealth Advisors LLC lifted its holdings in shares of DexCom by 14.8% during the first quarter. Fifth Third Wealth Advisors LLC now owns 7,043 shares of the medical device company's stock worth $481,000 after buying an additional 908 shares during the last quarter. Fulcrum Capital LLC bought a new stake in shares of DexCom in the first quarter valued at approximately $2,327,000. Finally, GAMMA Investing LLC grew its stake in shares of DexCom by 5,951.7% in the first quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock worth $34,128,000 after acquiring an additional 491,488 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM traded up $0.13 on Thursday, hitting $85.74. The company's stock had a trading volume of 2,358,616 shares, compared to its average volume of 4,337,465. The company has a market capitalization of $33.62 billion, a PE ratio of 59.96, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $120.48. The company has a 50 day moving average price of $75.64 and a 200 day moving average price of $78.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock valued at $6,103,505 over the last quarter. Corporate insiders own 0.32% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on DXCM shares. Robert W. Baird cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Barclays raised their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $98.32.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.